Welcome to our dedicated page for Beta Bionics SEC filings (Ticker: BBNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Beta Bionics, Inc. (Nasdaq: BBNX) provides access to the company’s official U.S. Securities and Exchange Commission disclosures. As a commercial-stage medical device company focused on the iLet Bionic Pancreas for insulin-requiring people with diabetes, Beta Bionics uses its filings to report financial results, operational metrics, and significant corporate events.
Investors can review current reports on Form 8-K, which the company uses to announce quarterly financial results and other material information. Recent 8-K filings reference press releases detailing net sales, gross margin, operating expenses, net loss, cash and investment balances, and non-GAAP measures such as adjusted EBITDA, along with reconciliations to the most directly comparable GAAP measures.
Filings also describe operational indicators that are central to Beta Bionics’ business, including installed customer base, new patient starts, and the mix of reimbursement between the Durable Medical Equipment channel and the Pharmacy Benefit Plan channel. These disclosures help readers understand how the iLet Bionic Pancreas is being adopted and reimbursed in practice.
In addition, the company has filed 8-Ks to furnish investor and analyst presentations and to summarize “real-world” iLet data. These materials discuss changes from baseline HbA1c to glucose management indicator, hypoglycemia metrics, and outcomes for users transitioning from multiple daily injections or competitive hybrid-closed loop systems, as well as analyses of usage patterns such as “fully-closed loop” operation.
Through its registration of common stock on the Nasdaq Global Market under the symbol BBNX, Beta Bionics is subject to ongoing reporting obligations. On this page, AI-powered tools can assist by summarizing lengthy filings, highlighting key figures and definitions, and helping readers navigate topics such as non-GAAP metrics, risk factor discussions, and descriptions of clinical and real-world data included in exhibits.
For anyone researching BBNX, the SEC filings page is a primary source for understanding the company’s reported financial condition, regulatory communications, and the detailed context behind its press releases and investor materials.
Form 144 notice from an insider of Beta Bionics, Inc. (BBNX) indicates a proposed brokered sale of 6,818 common shares through Merrill Lynch on 09/04/2025 to be executed on the NASDAQ. The filing shows the shares were acquired in two transactions: 2,069 shares from an equity award on 09/01/2025 and 4,749 shares from a stock option exercise on 09/04/2025, with payment listed as cash. The issuer's total shares outstanding are stated as 43,470,125, and the aggregate market value of the proposed sale is $136,179.70. The filing also discloses prior sales by the same person during the past three months totaling 16,158 and 868 shares on 08/19/2025 and 06/02/2025, respectively.
Stephen Feider, Chief Financial Officer of Beta Bionics, Inc. (BBNX), reported transactions dated 08/22/2025. He exercised an employee stock option with a $5.10 exercise price to acquire 4,413 shares and immediately sold those 4,413 shares pursuant to a Rule 10b5-1 plan adopted May 15, 2025, at a weighted average sale price of $17.014 per share (range $17.00–$17.12). After these transactions his beneficial ownership declined from 49,916 shares to 45,503 shares. The option vests in 48 equal monthly installments beginning 09/14/2023 and expires 09/13/2033.
Form 144 notice for Beta Bionics, Inc. (BBNX) reports a proposed sale of 4,413 shares of common stock through Merrill Lynch on 08/22/2025 with an aggregate market value of $75,082.65. The filing lists total shares outstanding of 43,470,125. The shares to be sold were acquired on 08/22/2025 as stock options from Beta Bionics and the stated payment method is cash. The filing also discloses two prior sales by Stephen Feider on 06/02/2025 (1,497 shares, $26,783.06) and 08/19/2025 (5,587 shares, $95,171.78).
Mark Hopman, Chief Commercial Officer of Beta Bionics, Inc. (BBNX), reported coordinated transactions on 08/19/2025 under a Rule 10b5-1 plan adopted May 13, 2025. He exercised an employee stock option with a $5.10 exercise price to acquire 16,158 shares. The same day he sold 16,158 shares pursuant to the 10b5-1 plan at a weighted average sale price of $16.6095, with reported price range of $16.26 to $17.1719. The filing shows beneficial ownership counts of 50,290 shares following the acquisition line and 34,132 shares following the reported sale; the derivative table reports 16,158 option shares underlying and 67,084 total shares beneficially owned following the derivative transaction line. The form is signed by an attorney-in-fact on 08/20/2025.
Stephen Feider, Chief Financial Officer of Beta Bionics, Inc. (BBNX), reported insider transactions on 08/19/2025. He acquired 5,587 shares via an employee stock option with an exercise price of $5.10 and immediately sold 5,587 shares pursuant to a Rule 10b5-1 plan at a weighted average price of $17.034505 (price range $17.00–$17.095). After these transactions his direct beneficial ownership decreased from 51,090 shares to 45,503 shares. The option shares vest in 48 equal monthly installments measured from September 14, 2023, and the related option lists an exercisable/expiration reference dated 09/13/2033.
Form 144 notice from Beta Bionics, Inc. (BBNX) records a proposed sale of 5,587 common shares through Merrill Lynch on the NASDAQ with an aggregate market value of $95,171.78, listed for sale on 08/19/2025. The shares were acquired by stock option from Beta Bionics with payment in cash on the same date. The filing also discloses a prior sale by Stephen Feider of 1,497 shares on 06/02/2025 for $26,783.06. By signing, the seller represents no undisclosed material adverse information exists and acknowledges potential criminal penalties for false statements.
Form 144 notice for Beta Bionics (BBNX) reports a proposed sale of 16,158 common shares through Merrill Lynch with an aggregate market value of $268,376.10. The filing lists 43,470,125 shares outstanding and an approximate sale date of 08/19/2025 on NASDAQ. The securities were acquired the same day (08/19/2025) via a stock option from Beta Bionics and payment is listed as cash. The filing also discloses a prior sale by Mark Hopman of 868 shares on 06/02/2025 for $15,529.00. The signer certifies they have no undisclosed material information and provides the standard Rule 10b5-1 and legal attestations.
This Schedule 13G/A discloses significant beneficial ownership positions in Beta Bionics common stock by Zone Healthcare, multiple Farallon-managed funds, their management company and numerous Farallon individual reporting persons. Zone Healthcare Holdings, LLC and Farallon Capital Management, L.L.C. are each reported with shared voting and dispositive power over 3,277,220 shares (7.6% of the class). Several Farallon funds disclose smaller direct holdings (examples include 166,877 and 380,597 shares). A set of Farallon individual reporting persons are each shown with an aggregate beneficial amount of 4,203,920 shares (9.7% of the class), and the filing states these individuals may be deemed beneficial owners based on their roles while disclaiming beneficial ownership.
The filing is submitted pursuant to the passive investor provision of the rules and includes a certification that the securities were not acquired to change or influence control. The Reporting Persons indicate they neither affirm nor disclaim the existence of a group among them and include standard power-of-attorney signatures for the reporting entities and individuals.
Beta Bionics reports that Sands Capital Life Sciences Pulse Fund II, Sands Capital Alternatives, LLC and Frank M. Sands jointly beneficially own 3,570,113 shares of common stock, equal to 8.2% of the class based on 43,470,125 shares outstanding as reported July 25, 2025. The filing shows 0 shares of sole voting or dispositive power and 3,570,113 shares of shared voting and dispositive power. The reporting parties file jointly and certify the holdings were not acquired to change or influence control of the issuer.
Morgan Stanley and its subsidiary Morgan Stanley Capital Services LLC have filed a Schedule 13G disclosing beneficial ownership of approximately 2.93 million Beta Bionics (BBNX) common shares, representing 6.8 % of the outstanding class as of 30 June 2025. All voting (2.93 m) and dispositive (2.93 m) rights are reported as shared; the firms hold no sole authority.
The filing was made under Rule 13d-1(b), signalling a passive investment. Morgan Stanley is classified as a parent holding company (HC), while the subsidiary is a broker-dealer (BD). The certification states the position was acquired in the ordinary course of business and not to influence control. A near-7 % institutional stake from a globally recognised financial institution may enhance BBNX’s liquidity, analyst coverage and investor credibility.